Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec 19;15(12):e50796.
doi: 10.7759/cureus.50796. eCollection 2023 Dec.

No Longer Cutaneous T-cell Lymphoma Dermal Nodule

Miranda L Yousif  1 , Xiangfeng Zhao  2 , Debora Andrews  3
Affiliations
Case Reports

No Longer Cutaneous T-cell Lymphoma Dermal Nodule

Miranda L Yousif et al. Cureus. .

Abstract

Primary cutaneous CD4+ small and medium pleomorphic T-cell lymphoproliferative disorder (PCSM-LPD) is a rare and typically asymptomatic proliferation of CD3+/CD4+ small and medium pleomorphic T-cells. In this case report, we share the details of a 41-year-old male presenting with a two-centimeter soft, mobile forehead nodule that was determined by clinical symptoms, histology, and immunostaining to be PCSM-LPD. We would like to emphasize the clinical resolution that was seen with minimal treatment.

Keywords: b lymphocytes; cutaneous t cell lymphoma; primary cutaneous cd4+ small/medium lymphoproliferative disorder; s100; t lymphocytes.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Primary cutaneous CD4+ T-cell lymphoproliferative disorder (immunohistochemistry, magnification 200x)
The lymphoma cells are positive for CD3.
Figure 2
Figure 2. Primary cutaneous CD4+ T-cell lymphoproliferative disorder (immunohistochemistry, magnification 200x)
The lymphoma cells are positive for CD4.
Figure 3
Figure 3. Primary cutaneous CD4+ T-cell lymphoproliferative disorder (immunohistochemistry, magnification 200x)
The lymphoma cells are positive for PD1.
Figure 4
Figure 4. Primary cutaneous CD4+ T-cell lymphoproliferative disorder (immunohistochemistry, magnification 200x)
The lymphoma cells are positive for S100.
Figure 5
Figure 5. Lateral view photograph of the lesion with clinical resolution following biopsy
Figure 6
Figure 6. Frontal view photograph of the lesion with clinical resolution following biopsy
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2017. Primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder; pp. 401–402.
    1. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. Garcia-Herrera A, Colomo L, Camós M, et al. J Clin Oncol. 2008;26:3364–3371. - PubMed
    1. The clinical spectrum of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder: an updated systematic literature review and case series. Surmanowicz P, Doherty S, Sivanand A, et al. J Invest Dermatol. 2021;141:0. - PubMed
    1. Rare cutaneous T-cell lymphomas. Damasco F, Akilov OE. Hematol Oncol Clin North Am. 2019;33:135–148. - PubMed
    1. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder-clinical and histopathologic features, differential diagnosis, and treatment. Gru AA, Wick MR, Eid M. Semin Cutan Med Surg. 2018;37:39–48. - PubMed

Publication types

LinkOut - more resources